Lineage Cell Therapeutics, Inc. (LCTX) — DEF 14A Filings
All DEF 14A filings from Lineage Cell Therapeutics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Lineage Cell Therapeutics DEF 14A: Executive Compensation Details
— Apr 29, 2025 Risk: medium
Lineage Cell Therapeutics, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2 -
Lineage Cell Therapeutics Files Definitive Proxy Statement
— Dec 9, 2024 Risk: low
Lineage Cell Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on December 9, 2024. This filing is related to the company's annual meeting and p -
Lineage Cell Therapeutics Announces 2024 Annual Meeting of Shareholders on June 11
— Apr 29, 2024 Risk: low
Lineage Cell Therapeutics, Inc. (LCTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual meeting scheduled for June 11, 2024, at 8:00 a.m
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX